225 related articles for article (PubMed ID: 35657206)
21. BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.
Sasaki-Saito N; Yamamura K; Hitaka T; Hirano Y; Nishihara K; Aoki M; Matsushita S
J Dermatol; 2023 Jan; 50(1):e28-e29. PubMed ID: 36217799
[No Abstract] [Full Text] [Related]
22. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
23. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS
Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196
[TBL] [Abstract][Full Text] [Related]
24. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
25. Binimetinib for the treatment of NRAS-mutant melanoma.
Queirolo P; Spagnolo F
Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
[TBL] [Abstract][Full Text] [Related]
26. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
27. Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.
Landras A; Reger de Moura C; Villoutreix BO; Battistella M; Sadoux A; Dumaz N; Menashi S; Fernández-Recio J; Lebbé C; Mourah S
Oncogene; 2022 Apr; 41(15):2254-2264. PubMed ID: 35217792
[TBL] [Abstract][Full Text] [Related]
28. A Preexisting Rare
Romano G; Chen PL; Song P; McQuade JL; Liang RJ; Liu M; Roh W; Duose DY; Carapeto FCL; Li J; Teh JLF; Aplin AE; Chen M; Zhang J; Lazar AJ; Davies MA; Futreal PA; Amaria RN; Zhang DY; Wargo JA; Kwong LN
Cancer Discov; 2018 May; 8(5):556-567. PubMed ID: 29496665
[TBL] [Abstract][Full Text] [Related]
29. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
Hong A; Piva M; Liu S; Hugo W; Lomeli SH; Zoete V; Randolph CE; Yang Z; Wang Y; Lee JJ; Lo SJ; Sun L; Vega-Crespo A; Garcia AJ; Shackelford DB; Dubinett SM; Scumpia PO; Byrum SD; Tackett AJ; Donahue TR; Michielin O; Holmen SL; Ribas A; Moriceau G; Lo RS
Cancer Discov; 2021 Mar; 11(3):714-735. PubMed ID: 33318037
[TBL] [Abstract][Full Text] [Related]
30. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.
Rebecca VW; Wood E; Fedorenko IV; Paraiso KH; Haarberg HE; Chen Y; Xiang Y; Sarnaik A; Gibney GT; Sondak VK; Koomen JM; Smalley KS
Mol Cell Proteomics; 2014 Jul; 13(7):1844-54. PubMed ID: 24760959
[TBL] [Abstract][Full Text] [Related]
31. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
Rebecca VW; Alicea GM; Paraiso KH; Lawrence H; Gibney GT; Smalley KS
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1154-8. PubMed ID: 25130256
[TBL] [Abstract][Full Text] [Related]
32. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
33. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.
Guhan SM; Shaughnessy M; Rajadurai A; Taylor M; Kumar R; Ji Z; Rashid S; Flaherty K; Tsao H
J Invest Dermatol; 2021 Aug; 141(8):2018-2027.e4. PubMed ID: 33745909
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.
Matter AV; Micaletto S; Urner-Bloch U; Dummer R; Goldinger SM
Oncologist; 2020 Nov; 25(11):e1593-e1597. PubMed ID: 32886824
[TBL] [Abstract][Full Text] [Related]
35. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
Hutchinson KE; Johnson DB; Johnson AS; Sanchez V; Kuba M; Lu P; Chen X; Kelley MC; Wang Q; Zhao Z; Kris M; Berger MF; Sosman JA; Pao W
Oncotarget; 2015 Sep; 6(26):22348-60. PubMed ID: 26084293
[TBL] [Abstract][Full Text] [Related]
36. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.
Vogel CJ; Smit MA; Maddalo G; Possik PA; Sparidans RW; van der Burg SH; Verdegaal EM; Heck AJ; Samatar AA; Beijnen JH; Altelaar AF; Peeper DS
Pigment Cell Melanoma Res; 2015 May; 28(3):307-17. PubMed ID: 25728708
[TBL] [Abstract][Full Text] [Related]
37. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
[TBL] [Abstract][Full Text] [Related]
38. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Algazi AP; Esteve-Puig R; Nosrati A; Hinds B; Hobbs-Muthukumar A; Nandoskar P; Ortiz-Urda S; Chapman PB; Daud A
Pigment Cell Melanoma Res; 2018 Jan; 31(1):110-114. PubMed ID: 28921907
[TBL] [Abstract][Full Text] [Related]
39. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
40. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
